CAR T Cell Therapys Market Size 2023 Is Expected To Expand At An Amazing Rate In The Upcoming Years 2028, According To New Report
The MarketWatch News Department was not involved in the creation of this content.
Feb 05, 2023 (The Expresswire) -- New report on Global "CAR T Cell Therapy Market " by Types (CD 19, CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, EGFRvlll) and end users/application (Acute Lymphocytic, Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Leukemia, Multiple Myeloma, Pancreatic Cancer, Neuroblasta, Breast Cancer, Acute Myeloid Leukemia, Hepatocellular Carcinoma, Colorectal Cancer),report provides understanding of detailed projections, product demand, and market sales are all abetted by a geographical study. It also includes comprehensive analysis of manufacturers with best facts and figures, meaning, Definition, SWOT and PESTAL analysis. Ask for a Sample Report
TOP MANUFACTURERS Listed in The CAR T Cell Therapy Market Report Are:
● Novartis International AG ● TILT Biotherapeutics ● Atara Biotherapeutics ● Legend Biotech ● Kite Pharma, Inc. ● Aurora Biopharma Inc. ● Sorrento Therapeutics Inc. ● Autolus ● Fortress Biotech ● Mustang Bio, Inc. ● CARsgen Therapeutics, Ltd. ● Immune Therapeutics ● Bellicum Pharmaceuticals, Inc. ● Bluebird Bio, Inc. ● Juno Therapeutics ● Eureka Therapeutics ● Celgene Corporation ● Pfizer, Inc.Get a Sample PDF of report at-https://www.Marketreportsworld.Com/enquiry/request-sample/18746722
Furthermore, CAR T Cell Therapy market research report gives insight on the global market's thorough competitive landscape. The research also includes a graphical overview of major organisations that includes their effective marketing strategies, market contribution, and recent advancements, market share by Type (CD 19, CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, EGFRvlll), Application (Acute Lymphocytic, Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Leukemia, Multiple Myeloma, Pancreatic Cancer, Neuroblasta, Breast Cancer, Acute Myeloid Leukemia, Hepatocellular Carcinoma, Colorectal Cancer) in both historical and current contexts.
"Browse Detailed TOC of CAR T Cell Therapy Market report, Tables and Figures with Charts that provides exclusive data, information, vital statistics, trends, and competitive landscape details in this niche sector."
In a nutshell, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the market in any manner.
Get a Sample Copy of the CAR T Cell Therapy Market Report 2023
CAR T Cell Therapy Market Report Overview:
The research report has incorporated the analysis of different factors that augment the market's growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones.
For the competitive landscape, the report also introduces players in the industry from the perspective of the market share, concentration ratio, etc., and describes the leading companies in detail, with which the readers can get a better idea of their competitors and acquire an in-depth understanding of the competitive situation. Further, mergers and acquisitions, emerging market trends, the impact of COVID-19, and regional conflicts will all be considered.
Competitor's/Manufacturer's details Mentioned in the reports are:
- Competitive Profile
- Performance Analysis with Product Profiles, Application and Specification
- Sales, Revenue, Price, Gross Margin
- Company Recent Development
- Strategies for Company to Deal with the Impact of COVID-19
CAR T Cell Therapy MarketProduct Insights:
Based on the CAR T Cell Therapy market development status, competitive landscape and development model in different regions of the world, this report is dedicated to providing niche markets, potential risks and comprehensive competitive strategy analysis in different fields. From the competitive advantages of different types of products and services, the development opportunities and consumption characteristics and structure analysis of the downstream application fields are all analysed in detail. To Boost Growth during the epidemic era, this report analyses in detail for the potential risks and opportunities which can be focused on.
Based on TYPE, the CAR T Cell Therapy market from 2023 to 2028 is primarily split into:
● CD 19 ● CD 20 ● GD2 ● CD22 ● CD30 ● CD33 ● HER1 ● HER2 ● Meso ● EGFRvlllBased on applications, the CAR T Cell Therapy market from 2023 to 2028 covers:
● Acute Lymphocytic ● Leukemia ● Chronic Lymphocytic Leukemia ● Non Hodgkin Leukemia ● Multiple Myeloma ● Pancreatic Cancer ● Neuroblasta ● Breast Cancer ● Acute Myeloid Leukemia ● Hepatocellular Carcinoma ● Colorectal CancerCOVID-19 AND RUSSIA-UKRAINE WAR INFLUENCE ANALYSIS:
The readers in the section will understand how the CAR T Cell Therapy market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
The CAR T Cell Therapy market revenue was Million USD in 2016, grew to Million USD in 2023, and will reach Million USD in 2028, with a CAGR of during 2023-2028.Considering the influence of COVID-19 on the global CAR T Cell Therapy market, this report analyzed the impact from both global and regional perspectives. From production end to consumption end in regions such as North America, Europe, China, and Japan, the report put emphasis on analysis of market under COVID-19 and corresponding response policy in different regions.
TO KNOW HOW COVID-19 PANDEMIC AND RUSSIA UKRAINE WAR WILL IMPACT THIS MARKET - REQUEST SAMPLE
Regional Insights:
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historical data and forecast (2017-2028) of the following regions are covered inthis report:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
CLIENT FOCUS OF THIS REPORT:
- Does this report consider the impact of COVID-19 and the Russia-Ukraine war on the CAR T Cell Therapy market?
Yes. As the COVID-19 and the Russia-Ukraine war are profoundly affecting the global supply chain relationship and raw material price system, we have definitely taken them into consideration throughout the research, and we elaborate at full length on the impact of the pandemic and the war on the CAR T Cell Therapy Industry.
- How do you determine the list of the key players included in the report?
With the aim of clearly revealing the competitive situation of the industry, we concretely analyze not only the leading enterprises that have a voice on a global scale, but also the regional small and medium-sized companies that play key roles and have plenty of potential growth.
Please find the key player list in Summary.
- What are your main data sources?
Both Primary and Secondary data sources are being used while compiling the report.
Primary sources include extensive interviews of key opinion leaders and industry experts (such as experienced front-line staff, directors, CEOs, and marketing executives), downstream distributors, as well as end-users.
Secondary sources include the research of the annual and financial reports of the top companies, public files, new journals, etc. We also cooperate with some third-party databases.
- Can I modify the scope of the report and customize it to suit my requirements?
Yes. Customized requirements of multi-dimensional, deep-level and high-quality can help our customers precisely grasp market opportunities, effortlessly confront market challenges, properly formulate market strategies and act promptly, thus to win them sufficient time and space for market competition.
Chapters Included in CAR T Cell Therapy Market Report: -
Chapter 1 provides an overview of CAR T Cell Therapy market, containing global revenue and CAGR. The forecast and analysis of CAR T Cell Therapy market by type, application, and region are also presented in this chapter.
Chapter 2 is about the market landscape and major players. It provides competitive situation and market concentration status along with the basic information of these players.
Chapter 3 introduces the industrial chain of Polyurethane Elastic Sealant and MS Sealant. Industrial chain analysis, raw material (suppliers, price, supply and demand, market concentration rate) and downstream buyers are analyzed in this chapter.
Chapter 4 concentrates on manufacturing analysis, including cost structure analysis and process analysis, making up a comprehensive analysis of manufacturing cost.
Chapter 5 provides clear insights into market dynamics, the influence of COVID-19 in CAR T Cell Therapy industry, consumer behavior analysis.
Chapter 6 provides a full-scale analysis of major players in CAR T Cell Therapy industry. The basic information, as well as the profiles, applications and specifications of products market performance along with Business Overview are offered.
Chapter 7 pays attention to the sales, revenue, price and gross margin of CAR T Cell Therapy in markets of different regions. The analysis on sales, revenue, price and gross margin of the global market is covered in this part.
Chapter 8 gives a worldwide view of CAR T Cell Therapy market. It includes sales, revenue, price, market share and the growth rate by type.
Chapter 9 focuses on the application of Polyurethane Elastic Sealant and MS Sealant, by analyzing the consumption and its growth rate of each application.
Chapter 10 prospects the whole CAR T Cell Therapy market, including the global sales and revenue forecast, regional forecast. It also foresees the CAR T Cell Therapy market by type and application.
Enquire before Purchasing this report at- https://www.Marketreportsworld.Com/enquiry/pre-order-enquiry/18746722
Years considered for this report:
Historical Years: 2016-2023
Base Year: 2023
Estimated Year: 2023
Forecast Period: 2023-2028
Key highlights of the report:
- Define, describe and forecast CAR T Cell Therapy product market by type, application, end user and region.
- Provide enterprise external environment analysis and PEST analysis.
- Provide strategies for company to deal with the impact of COVID-19.
- Provide market dynamic analysis, including market driving factors, market development constraints.
- Provide market entry strategy analysis for new players or players who are ready to enter the market, including market segment definition, client analysis, distribution model, product messaging and positioning, and price strategy analysis.
- Keep up with international market trends and provide analysis of the impact of the COVID-19 epidemic on major regions of the world.
- Analyze the market opportunities of stakeholders and provide market leaders with details of the competitive landscape.
Buy this report (Price 4000 USD for single user license) at- https://www.Marketreportsworld.Com/purchase/18746722
Detailed TOC of 2023-2028 Global CAR T Cell Therapy Professional Market Research Report, Analysis from Perspective of Segmentation (Competitor Landscape, Type, Application, and Geography)
1 CAR T Cell Therapy Market Overview
1.1 Product Overview and Scope of Polyurethane Elastic Sealant and MS Sealant
1.2 CAR T Cell Therapy Segment by Type
1.3 Global CAR T Cell Therapy Segment by Application
1.4 Global CAR T Cell Therapy Market, Region Wise (2017-2023)
1.5 Global Market Size of CAR T Cell Therapy (2017-2028)
2 Global CAR T Cell Therapy Market Landscape by Player
2.1 Global CAR T Cell Therapy Sales and Share by Player (2017-2023)
2.2 Global CAR T Cell Therapy Revenue and Market Share by Player (2017-2023)
2.3 Global CAR T Cell Therapy Average Price by Player (2017-2023)
2.4 Global CAR T Cell Therapy Gross Margin by Player (2017-2023)
2.5 CAR T Cell Therapy Manufacturing Base Distribution, Sales Area and Product Type by Player
2.6 CAR T Cell Therapy Market Competitive Situation and Trends
3 CAR T Cell Therapy Upstream and Downstream Analysis
3.1 CAR T Cell Therapy Industrial Chain Analysis
3.2 Key Raw Materials Suppliers and Price Analysis
3.3 Key Raw Materials Supply and Demand Analysis
3.4 Manufacturing Process Analysis
3.5 Market Concentration Rate of Raw Materials
3.6 Downstream Buyers
3.7 Value Chain Status Under COVID-19
Get a Sample Copy of the CAR T Cell Therapy Market Report 2023
4 CAR T Cell Therapy Manufacturing Cost Analysis
4.1 Manufacturing Cost Structure Analysis
4.2 CAR T Cell Therapy Key Raw Materials Cost Analysis
4.3 Labor Cost Analysis
4.4 Energy Costs Analysis
4.5 RandD Costs Analysis
5 Market Dynamics
5.1 Drivers
5.2 Restraints and Challenges
5.3 Opportunities
5.4 CAR T Cell Therapy Industry Development Trends under COVID-19 Outbreak
5.5 Consumer Behavior Analysis
6 Players Profiles
7 Global CAR T Cell Therapy Sales and Revenue Region Wise (2017-2023)
7.1 Global CAR T Cell Therapy Sales and Market Share, Region Wise (2017-2023)
7.2 Global CAR T Cell Therapy Revenue (Revenue) and Market Share, Region Wise (2017-2023)
8 Global CAR T Cell Therapy Sales, Revenue (Revenue), Price Trend by Type
8.1 Global CAR T Cell Therapy Sales and Market Share by Type (2017-2023)
8.2 Global CAR T Cell Therapy Revenue and Market Share by Type (2017-2023)
8.3 Global CAR T Cell Therapy Price by Type (2017-2023)
8.4 Global CAR T Cell Therapy Sales Growth Rate by Type (2017-2023)
8.4.2 Global CAR T Cell Therapy Sales Growth Rate of MS Sealant (2017-2023)
9 Global CAR T Cell Therapy Market Analysis by Application
9.1 Global CAR T Cell Therapy Consumption and Market Share by Application (2017-2023)
9.2 Global CAR T Cell Therapy Consumption Growth Rate by Application (2017-2023)
10 Global CAR T Cell Therapy Market Forecast (2023-2028)
10.1 Global CAR T Cell Therapy Sales, Revenue Forecast (2023-2028)
10.2 Global CAR T Cell Therapy Sales and Revenue Forecast, Region Wise (2023-2028)
10.3 Global CAR T Cell Therapy Sales, Revenue and Price Forecast by Type (2023-2028)
10.4 Global CAR T Cell Therapy Consumption Forecast by Application (2023-2028)
10.5 CAR T Cell Therapy Market Forecast Under COVID-19
11 Research Findings and Conclusion
Browse complete TOC at-https://www.Marketreportsworld.Com/TOC/18746722
About Us:
Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided today bsusinesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors.Market Reports Worldis the credible source for gaining the market reports that will provide you with the lead your business needs.
Contact Us:
Email: sales@marketreportsworld.Com
Phone: US +(1) 424 253 0946 /UK +(44) 203 239 8187
Web: https://www.Marketreportsworld.Com
Our Other Reports:
Stainless Steel Kitchen Utensils Market (New Report 2023): A complete research On Current and Upcoming Trends, Growth and Opportunities till 2028
Low-Frequency Sine Wave Neurostimulation Therapy Devices Market 2023: Along with Competitors Statistics, Growth, Trends with Current Market Scenario till 2028
Crawler Carriers Market 2023 Will Witness a Huge Rise in Revenues by 2027 With 4.6% CAGR| 108 Pages Report
Bioresorbable Medical Material Market (New Report): Size is set to Grow at a Remarkable Pace CAGR of 9.3% in the Upcoming Years (2023-2027)
Tablet Stylus Pens Market (New Report): Size is set to Grow at a Remarkable Pace CAGR of 3.8% in the Upcoming Years (2023-2027)
Press Release Distributed by The Express Wire
To view the original version on The Express Wire visit CAR T Cell Therapys Market Size 2023 is Expected to Expand at an Amazing Rate in the Upcoming Years 2028, According to New Report
COMTEX_423916277/2598/2023-02-05T22:28:15
Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.Com. You can also contact MarketWatch Customer Service via our Customer Center.
The MarketWatch News Department was not involved in the creation of this content.
CAR T Cell Therapy
What is CAR T cell therapy?CAR T cell therapy is a treatment for some types of leukemia and non-Hodgkin lymphoma. T cells are part of the immune system that “hook” onto cancer cells and kill them. In CAR T cell therapy, doctors take T cells from the patient’s blood and add a new “hook” called a CAR. Together, these are called CAR T cells. The patient gets the CAR T cells back through an IV. The CAR T cells find, attack, and kill the cancer cells in the patient’s body.
Who is eligible to receive CAR T cell therapy?Currently, CAR T cell therapy is FDA approved as standard of care for some forms of non-Hodgkin lymphoma and a type of leukemia. These include acute lymphoblastic leukemia (only available for patients up to age 26), and certain types of large B-cell lymphoma.
Will my insurance cover CAR T cell therapy?Health insurers are still deciding on their coverage policies for CAR T cell therapy. In the meantime, they review coverage on a case-by-case basis. This is usual when new therapies are first approved. HCI's billing and financial services staff will work with patients and insurers to seek health insurance coverage for patients who need CAR T cell therapy.
What are the possible side effects of CAR T Cell therapy?CAR T cell therapy can have serious side effects. Your care team will watch for them. It’s important that you and your caregivers know the signs of these side effects. Treating the side effects early can help you recover.
If CAR T cell treatment is right for you, your care team collects your T cells with a process called apheresis. Your blood goes through a machine that separates and collects your T cells. The rest of the blood goes back into your body.
We send your collected T cells to a lab where CAR “hooks” are attached to them. This turns them into CAR T cells.
Before you get your CAR T cells back, you will get chemotherapy to prepare your body for treatment.
When your CAR T cells come from the lab, we put them back in your body by infusion into a vein. This happens in the hospital.
What is the recovery process like?After your infusion of CAR T cells, you will stay in the hospital for up to two weeks. If your symptoms are severe, you may need to stay in our cancer intensive cancer care unit. After you leave the hospital, you must plan to stay within 40 miles, or sixty minutes, of HCI for 30 days. This allows your care team to watch for any side effects of the treatment and help you with them.
What if I’m not local, and I’m receiving CAR T cell therapy treatment at HCI?HCI offers housing nearby for patients and families who are receiving cancer treatment and care. Guests may consider resources including University of Utah Patient and Family Housing or the American Cancer Society Hope Lodge.
First CAR T-cell Therapy Recommended For Routine Use On The NHS In England
First CAR T-cell therapy recommended for routine use on the NHS in England
- Eligible adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) who have received 2 or more systemic therapies will have long-term NHS access to this treatment -
26th JANUARY 2023, LONDON, UK – Gilead Sciences Ltd. And Kite, a Gilead company, today announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta®[1] ▼ (axicabtagene ciloleucel; axi-cel) for routine commissioning on the NHS in England for the treatment of some adults with certain forms of lymphoma. Specifically, patients with diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) who have already been treated with 2 or more systemic therapies may be eligible for treatment. Through the Cancer Drugs Fund, in 2018, England was the first country in Europe to provide access to a chimeric antigen receptor (CAR) T-cell therapy to treat these blood cancers, and since then over 500 patients in England have received axi-cel.
Dr Graham Collins, Consultant Haematologist at Oxford University Hospitals NHS Foundation Trust said: “Since the earliest clinical trial data on CAR T-cell therapies were presented, there has been excitement in the clinical community about their potential to help fight cancer. Today’s news is encouraging as it shows that even in the real-world setting, these therapies are living up to their expectations for patients with aggressive forms of lymphoma. Importantly, it means some patients who have received prior treatment have the potential to face a different outlook on their prognosis.”
CAR T-cell therapy is an individualised treatment for patients that is currently licensed for people living with some types of advanced blood cancer. CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells.
Dr Véronique Walsh, Vice President and General Manager, Gilead Sciences UK & Ireland said: “We are pleased to announce that, moving forward, axi-cel will be routinely available in the third line setting for all eligible DLBCL and PMBCL patients on the NHS. This news comes at a time when new hospitals are preparing to deliver CAR T-cell therapies, and will mean that healthcare professionals in these centres will have this treatment as an important option for their patients.”
DLBCL and PMBCL are both aggressive forms of non-Hodgkin lymphoma. Around 14,200 cases of non-Hodgkin lymphoma are diagnosed in the UK each year, of which approximately 5,500 are diagnosed with DLBCL and 330 with PMBCL.[1],[2],[3] After initial chemotherapy, up to 45% of patients with DLBCL will require a second line treatment, which often involves high dose chemotherapy and a stem cell transplant.[4] Of those who receive a transplant, about 50% will ultimately relapse.[5] This decision ensures that these patients in the third line setting will continue to have access to CAR T-cell therapy.
Overall, survival of DLBCL significantly lags behind the average for all blood cancers, with only 60% of people living with this aggressive form of cancer surviving for 5 years compared to 70% across blood cancers more generally.[6],[7]
Helen Rowntree, CEO at Blood Cancer UK said: “CAR-T therapies offer hope to people who are living with the most aggressive forms of blood cancer. For people living with diffuse large B-cell lymphoma, the risk of recurrence and uncertainty about which treatment options will be available to them can add distress at an already very difficult time. We’re pleased that this CAR T-cell therapy can be a viable option for certain blood cancer patients in the long term. It gives people who find themselves in this position more clarity about their treatment options.”
Helen continued “It also demonstrates the benefit of the NHS England’s Cancer Drugs Fund, which led to many accessing this drug in the period of time when NICE was gathering evidence and deliberating on its cost-effectiveness. All in all, it’s good news for people with blood cancer, however we know there’s more work to do, because still too many people are dying of blood cancer.”
NOTES TO EDITORS
About axicabtagene ciloleucel (axi-cel)[8]
Axi-cel is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of:
As part of the therapy, T-cells are drawn from a patient’s blood and reprogrammed in a lab to create T-cells that are genetically engineered to kill cancer cells. Axi-cel is administered to the patient via a single intravenous infusion following the administration of a round of chemotherapy designed to accommodate the new cells and minimise the patient’s immune reaction to them.
Axi-cel was investigated in the pivotal ZUMA-1 trial (NCT02348216) of patients with refractory large B-cell lymphoma. In the single-arm trial - a pivotal analysis as assessed by an independent review committee - 72% of patients (n=73/101) who received a single infusion of axi-cel responded to therapy, with 51% (n=52/101) achieving a complete response (CR) with a median follow-up of 15.1 months.8
In the five-year follow up analysis of the ZUMA-1 trial, among all patients treated with axi-cel, the five-year OS rate was 42.6% (95% CI, 32.8 – 51.9).[9] Among patients who had a CR, the five-year OS rate was 64.4% (95% CI, 50.8 – 75.1) and median survival time has yet to be reached. Between the 4 and 5 year analysis, 92% of patients remained alive and have received no additional treatment since their one-time infusion of axi-cel.
Axi-cel may cause side effects that are severe or life-threatening, such as cytokine release syndrome (CRS) or neurological toxicities. In ZUMA-1, 11% of patients experienced Grade 3 or higher CRS and 31% experienced Grade 3 or higher neurologic toxicities.8 Overall, 98% of patients recovered from CRS and/or neurologic adverse reactions.8 Treatment algorithms have been developed to manage some of the symptoms associated with both CRS and neurologic adverse reactions experienced by patients on axi-cel.
Grade 3 or higher non-haematological adverse reactions included encephalopathy, unspecified pathogen infections, CRS, bacterial infection, delirium, hypertension,
hypotension, transaminases increased, and viral infection. The most common Grade 3 or higher haematological adverse reactions included lymphopenia, leukopenia, neutropenia, anaemia, and thrombocytopenia.8
For full details on the Special Warnings and Precautions for Use and Adverse Reactions (including appropriate management), please refer to the GB Summary of Product Characteristics (SmPC).8
About Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, with manufacturing operations in North America and Europe. Kite’s singular focus is cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has more approved CAR T indications to help more patients than any other company.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. For the UK, reporting forms and information can be found at www.Mhra.Gov.Uk/yellowcard or via the Yellow Card app (downloadable from the Apple app store or Google Play store). Adverse events should also be reported to Gilead at Safety_FC@gilead.Com or +44 (0) 1223 897500.
++++
[1] Cancer Research UK. What is non-Hodgkin lymphoma? Available at: https://www.Cancerresearchuk.Org/about-cancer/non-hodgkin-lymphoma/about. Last accessed: January 2023.
[2] Cancer Research UK. Diffuse large B cell lymphoma. Available at: https://www.Cancerresearchuk.Org/about-cancer/non-hodgkin-lymphoma/types/diffuse-large-B-cell-lymphoma. Last accessed: January 2023.
[3] Dabrowska-Iwanicka A, Walewski JA. Primary mediastinal large B-cell lymphoma. Curr Hematol Malig Rep. 2014 Sep;9(3):273-83. Https://doi.Org/10.1007/s11899-014-0219-0.
[4] Chaganti, S., Illidge, T., Barrington, S., et al. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016 174: 43-56. https://doi.Org/10.1111/bjh.14136.
[5] Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017 Oct 19;130(16):1800-1808. Https://doi.Org/10.1182/blood-2017-03-769620.
[6] Cancer Research UK. Survival. Available at: https://www.Cancerresearchuk.Org/about-cancer/non-hodgkin-lymphoma/survival#:~:text=Generally%20for%20people%20with%20DLBCL,or%20more%20after%20their%20diagnosis. Last accessed: January 2023.
[7] Blood Cancer UK. Facts and information about blood cancer. Available at: https://bloodcancer.Org.Uk/news/blood-cancer-facts/#:~:text=Overall,%20the%20five-year%20survival,who%20doesn't%20have%20cancer. Last accessed: January 2023.
[8] Yescarta. Summary of Product Characteristics. Updated December 2022. Available at: https://www.Medicines.Org.Uk/emc/product/9439/smpc#gref. Last accessed: January 2023
[9] Jacobson C, Locke FL, Ghobadi A, et al. Long-term (4- and 5- Year) overall survival in ZUMA-1, the pivotal study of axicabtagene ciloleucel in patients with refractory large B-cell lymphoma poster slides. Presented at: 2021 ASH; December 17, 2021; Atlanta, GA.
